Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: CRX
Latest Price: 5.50p  (0,00%)
52-week High: 6.75p
52-week Low: 2.75p
Market Cap: 12.30M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Cyprotex
www.cyprotex.com

Cyprotex is a preclinical discovery/development contract research organisation with a core focus
in analysing the ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic properties
of potential new drugs.

Full Cyprotex profile here
Is CRX a Buy, Sell or Hold?Get your FREE analysis of CRX
Pdf

Cyprotex Announces Free Access to its Database for Researchers.

1st Sep 2010, 1:11 pm Cyprotex specialises in the preclinical ADME assessment of drug candidates

Researchers will now have free online access to AIM listed Cyprotex PLC's (LON:CRX) database of the ADME and pharmacokinetic properties of marketed drugs, the company announced today.

Cyprotex provides data about potential new drugs and specialises in the preclinical ADME assessment of drug candidates.

ADME stands for absorption, distribution, metabolism and excretion.

Access to the database is through the company's online visualisation tool, Cloe® Knowledge, available via Cyprotex's Cloe® Gateway online portal: www.cloegateway.com.

The firm said that Cloe® Knowledge categorises marketed drugs according to the 2009 WHO ATC/DDD drug index, which allows the database to be searchable by therapeutic area. 

Cloe® Knowledge's compound property visualisation tools allow relationships between different ADME and phys-chem properties to be viewed on either 2D or 3D scatter plots, said the company.

Cyprotex CEO Dr Anthony D Baxter said: "Cyprotex believes in sharing its knowledge with the scientific community. 

"Our Cloe®Knowledge database of marketed drugs has been compiled and continuously updated based on extensive literature values and data generated in our own laboratories. 

"Although some of the data are already available in the public domain, often they have not been conveniently compiled, and certainly not accessible through a powerful visualisation and interpretation tool such as the one Cloe® Knowledge provides. 

"We believe that free access to these data via Cloe® Knowledge will help advance drug discovery, especially within the resource-constrained academic community."

On August 20 this year, the company announced the launch of its new in vitro toxicology service and the addition of 90 square metres to its Macclesfield facility to support the new service.

This gave the site the same in vitro toxicology capabilities as those of its recently acquired research lab Apredica in Watertown, Massachusetts.

The Boston, MA based Apredica was acquired for £2.68 million in early August, giving Cyprotex an operational base in the US, the largest market for the company's combined services as well as immediate entry and credibility in the in vitro toxicology market.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.